Hence, targeting CXCL1/CXCR2 signaling has emerged as a pivotal strategy for improving the prognosis of breast cancer, with potential benefits for patients resistant to chemotherapy through the use of CXCL1/CXCR2 antagonists. This evidence concerns the gene CXCL1 and breast cancer.